Compliance with an asthma care discharge plan decreases readmissions

Food Insecurity and the Dangers of Infant Formula Dilution

A recap of the FDA submissions and regulatory decisions in pediatrics from January 2025.

January 30th 2023

Phase 3: Delgocitinib improves chronic hand eczema in adolescents

February 4th 2025

Demystifying Infant Formula

The primary and all key secondary endpoints were met compared to cream vehicle in the phase 3 DELTA TEEN trial.

October 11th 2022

FDA approves tocilizumab-anoh as biosimilar for multiple diseases

Weekly review: Changing atopic dermatology treatments, new puzzler, more

As a biosimilar to Actemra, tocilizumab-anoh in both IV and SC formulation is approved to treat rheumatoid arthritis, pJIA, sJIA, COVID-19, and giant cell arteritis.

FDA news in pediatrics: January 2025

Get caught up with Contemporary Pediatrics! This list helps you navigate our top stories from the week, all in one place.

Related Content

Patrick Campbell

February 5th 2025

Food Insecurity and the Dangers of Infant Formula Dilution

A recap of the FDA submissions and regulatory decisions in pediatrics from January 2025.

January 30th 2023

Phase 3: Delgocitinib improves chronic hand eczema in adolescents

February 4th 2025

Demystifying Infant Formula

The primary and all key secondary endpoints were met compared to cream vehicle in the phase 3 DELTA TEEN trial.

October 11th 2022

FDA approves tocilizumab-anoh as biosimilar for multiple diseases

Weekly review: Changing atopic dermatology treatments, new puzzler, more

As a biosimilar to Actemra, tocilizumab-anoh in both IV and SC formulation is approved to treat rheumatoid arthritis, pJIA, sJIA, COVID-19, and giant cell arteritis.